Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
99 hedge funds and large institutions have $61.4M invested in Infinity Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 19 closing their positions.
14% more capital invested
Capital invested by funds: $53.9M → $61.4M (+$7.57M)
7% less funds holding
Funds holding: 107 → 99 (-8)
16% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 31
30% less call options, than puts
Call options by funds: $138K | Put options by funds: $197K
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.43M |
| 2 |
Renaissance Technologies
New York
|
+$1.71M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$892K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$451K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$415K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.07M |
| 2 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
-$931K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$863K |
| 4 |
Millennium Management
New York
|
-$860K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$536K |
INFI Hedge Fund Activity: Q3 2016 in Review
99 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2016, worth a combined $61.4M — up 14% from $53.9M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of INFI and 13 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 26 added.
The largest buyer was Wellington Management Group, adding an estimated $2.43M. The largest seller was Vanguard Group, cutting an estimated $1.07M.
- 99 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2016, down from 107 in Q2 2016.
- Funds reported $61.4M of Infinity Pharmaceuticals, Inc. stock for Q3 2016, up 14% quarter-over-quarter.
- 13 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2016 and 19 closed out, a net change of -6 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2016 was Wellington Management Group, an estimated $2.43M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2016 was Vanguard Group, an estimated $1.07M sold.
Based on aggregated 13F filings for Q3 2016.